Benchmark starts Insulet at Buy

Benchmark sees a 22% upside for shares of Insulet (PODD) as analyst Jan Wald says an active third manufacturing line will likely alleviate tight OmniPod inventory.

"We believe that greater customer retention, better market penetration as evidenced by new prescribers and improved margins from the new OmniPod insulin pump should drive upside in the shares," Wald adds.

Shares initiated at Buy, price target is $44.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs